Private Advisor Group LLC Sells 25,200 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Private Advisor Group LLC lowered its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 48.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 26,992 shares of the company’s stock after selling 25,200 shares during the quarter. Private Advisor Group LLC’s holdings in Amneal Pharmaceuticals were worth $225,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. increased its stake in Amneal Pharmaceuticals by 0.6% in the first quarter. Vanguard Group Inc. now owns 13,728,233 shares of the company’s stock valued at $83,193,000 after acquiring an additional 85,846 shares during the period. Hillsdale Investment Management Inc. raised its holdings in shares of Amneal Pharmaceuticals by 19.7% in the 1st quarter. Hillsdale Investment Management Inc. now owns 699,719 shares of the company’s stock worth $4,240,000 after buying an additional 115,100 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Amneal Pharmaceuticals by 20.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 751,403 shares of the company’s stock valued at $4,771,000 after buying an additional 128,772 shares in the last quarter. CANADA LIFE ASSURANCE Co boosted its stake in Amneal Pharmaceuticals by 417.8% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 36,106 shares of the company’s stock valued at $218,000 after buying an additional 29,133 shares in the last quarter. Finally, Acadian Asset Management LLC boosted its stake in Amneal Pharmaceuticals by 701.8% in the 2nd quarter. Acadian Asset Management LLC now owns 811,853 shares of the company’s stock valued at $5,148,000 after buying an additional 710,598 shares in the last quarter. Institutional investors and hedge funds own 31.82% of the company’s stock.

Amneal Pharmaceuticals Stock Performance

Shares of AMRX stock opened at $8.61 on Friday. The stock’s fifty day moving average is $8.53 and its 200-day moving average is $7.51. Amneal Pharmaceuticals, Inc. has a 52 week low of $3.96 and a 52 week high of $8.95. The stock has a market capitalization of $2.67 billion, a PE ratio of -13.89 and a beta of 1.17.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its earnings results on Friday, August 9th. The company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.11 by $0.04. Amneal Pharmaceuticals had a negative net margin of 6.72% and a positive return on equity of 1,235.03%. The company had revenue of $701.78 million during the quarter, compared to the consensus estimate of $657.43 million. As a group, analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.52 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on AMRX shares. Barclays lifted their price objective on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the company an “overweight” rating in a report on Tuesday, August 13th. Truist Financial lifted their price target on shares of Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a report on Wednesday, October 2nd. Finally, JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price target on the stock in a research report on Friday, September 6th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $9.40.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.